Program Director/Principal Investigator (Last, First, Middle): T o t O , R o b e r t D . PROJECT SUMMARY (See instmctions): The CTSA has had a major impact on the clinical and translational research (CTR) environment at UT Southwestern. Many new and highly successful programs in education and training, pilot grant awards, biomedical informatics (BMI), biostatistics, population research, community health sciences, and patient- centered outcomes research have been established. Concurrently, the CTSA stimulated UT Southwestern to invest heavily in CTR infrastructure by recruiting new clinical and translational researchers into leadership positions of major clinical departments, by creating a new research institute that focuses on stem cell biology and cancer and by greatly enhancing genomics, metabolomics, proteomics, bioinformatics, and systems biology. Two new, state-of-the art hospitals are under construction, to open in fall 2014, and they incorporate design elements that will support CTR. Our vision is to accelerate translation of new discoveries into clinical practice (T0-T4) by leveraging our scientific strengths. We will integrate and centralize our resources to work in an encouraging and collaborative research environment. Our three Specific Aims are to: 1) Enhance our Research Environment to Accelerate Translation of Discovery into Practice. We formed the Center for Translational Medicine (Center), directed by the CTSA PI, to serve as the new integrated home for our CTSA. The Center will coordinate and expand the clinical research enterprise while it educates clinical and translational researchers at every level. 2) Leverage Existinq and New Resources to Build on Four Innovative Programs in Translation including: a) Target Identification and Validation;b) Discovery in Humans;c) Intervention in Humans and d) Population Science and Community Engagement. 3) Share Knowledge and Discoverv. and Contribute to the Leadership of the National Consortium. We will share gains that are made in our programs in educational and translational research programs with the Texas Regional CTSA consortium and National CTSA Consortium. We will contribute to leadership in areas of translation including T0-T4 research, and discovery and commercialization of new drugs and devices. Our vision for accelerating CTR is well aligned with the new NCATS initiatives and takes full advantage of gains made in the previous funding. We will establish new and improved programs that will enable investigators to discover, translate and disseminate new knowledge that will improve the prevention, detection, diagnosis, and effective treatment of disease.

Public Health Relevance

Improving the health of our nation requires a concerted effort by medical scientists, health care providers and public health policymakers. This grant application will provide the crucial infrastructure necessary for medical scientists to discover and apply new diagnostics and therapeutics for the detection, prevention, detection, diagnosis and effective treatment of disease. The goal is to accelerate the movement of these new discoveries into clinical practice to improve our nation's health in a safe and effective manner.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
3UL1TR001105-02S1
Application #
8915945
Study Section
Special Emphasis Panel (ZAI1-PTM-C (S2))
Program Officer
Talbot, Bernard
Project Start
2013-09-26
Project End
2018-04-30
Budget Start
2014-09-05
Budget End
2015-03-04
Support Year
2
Fiscal Year
2014
Total Cost
$97,249
Indirect Cost
$36,086
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Gill, Michelle A; Liu, Andrew H; Calatroni, Agustin et al. (2018) Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol 141:1735-1743.e9
Brusco, Lauren L; Wathoo, Chetna; Mills Shaw, Kenna R et al. (2018) Physician interpretation of genomic test results and treatment selection. Cancer 124:966-972
Nassour, Ibrahim; Hynan, Linda S; Christie, Alana et al. (2018) Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study. J Gastrointest Surg 22:695-702
Das, Bibhuti B; Lacelle, Chantale; Zhang, Song et al. (2018) Complement (C1q) Binding De Novo Donor-Specific Antibodies and Cardiac-Allograft Vasculopathy in Pediatric Heart Transplant Recipients. Transplantation 102:502-509
Karp, David R; Chong, Benjamin F; James, Judith A et al. (2018) Mock Recruitment for the Study of Antimalarials in Incomplete Lupus Erythematosus Trial. Arthritis Care Res (Hoboken) :
Jain, Snigdha; Khera, Rohan; Mortensen, Eric M et al. (2018) Readmissions of adults within three age groups following hospitalization for pneumonia: Analysis from the Nationwide Readmissions Database. PLoS One 13:e0203375
Khera, Rohan; Lu, Yuan; Lu, Jiapeng et al. (2018) Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study. BMJ 362:k2357
Chindhy, Shahzad; Joshi, Parag; Khera, Amit et al. (2018) Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events. J Am Coll Cardiol 72:698-700
Neeland, Ian J; Singh, Shruti; McGuire, Darren K et al. (2018) Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study. Diabetologia 61:2570-2579
Kunzler, Elaine; Hynan, Linda S; Chong, Benjamin F (2018) Autoimmune Diseases in Patients With Cutaneous Lupus Erythematosus. JAMA Dermatol 154:712-716

Showing the most recent 10 out of 520 publications